Clinical Trial Update: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

View source ↗

Summary

Expanded access protocol update for a single HIV patient who completed 24 weeks of treatment in CytoDyn's PR0140_CD02 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PRO 140 (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV | Status: NO_LONGER_AVAILABLE